Cancer treatment is often imagined as an endpoint: chemotherapy ends, scans return clear, and life resumes. Yet, for many patients, the fear of recurrence never fully disappears, as the constant fear of the cancer recurring is always in the back of their mind. This tension between progress and uncertainty reflects a broader challenge in modern oncology: despite increasingly advanced treatments, cancer frequently returns.
Over the past several decades, the field of oncology has made remarkable progress. Chemotherapy regimens have become more refined, radiation therapies more precise, and targeted drugs increasingly personalized. These advances have improved short-term survival and quality of life for many patients. However, long-term outcomes tell a more sobering story. Recurrence rates remain high across a wide range of cancers, including breast, bladder, pancreatic, and blood cancers, with particularly aggressive cancers such as glioblastoma often returning with near certainty. These trends reveal a critical gap in cancer care, as many existing treatments are effective at short term disease suppression, but far less successful at preventing its return.
Modern cancer care has increasingly turned to genetic testing to better understand this problem. By sequencing a tumor’s DNA, clinicians can identify patient-specific mutations that drive cancer growth and use that information to guide treatment decisions. This approach has become a standard component of oncology practice and has improved physicians’ ability to predict which therapies may be effective for individual patients. However, genetic testing alone remains largely descriptive. While it can identify problematic mutations, it does not actively correct them. Cancer cells can continue to adapt, acquire new mutations, and survive in small numbers, eventually re-emerging as recurrent disease.
It is within this broader context that Sanchali Tiwari situates her manuscript, Advancing Oncology Treatments Through Genetic Engineering. Tiwari synthesizes existing studies, clinical cases, and technological developments to examine why current cancer treatments struggle to provide durable protection against relapse. Her central focus is not on eliminating tumors alone, but on rethinking how cancer is treated at its most fundamental, genetic level.
Tiwari highlights genetic engineering as a promising response to the limitations of conventional therapies. Genetic engineering refers to a group of laboratory-based techniques that allow scientists to directly alter DNA. One of the most well-known tools in this field is CRISPR-Cas9, which functions like a pair of molecular scissors guided by a programmable sequence. Scientists can direct CRISPR to a specific section of DNA, where it can cut, disable, or modify genes with high precision. In cancer research, this precision allows for targeted intervention at the genetic level rather than relying on treatments that broadly affect entire populations of cells.
This approach contrasts sharply with traditional chemotherapy, which targets all fast-dividing cells regardless of whether they are cancerous. While effective at shrinking tumors, chemotherapy often damages healthy tissues such as hair follicles and cells lining the digestive tract, leading to significant side effects. Genetic engineering, by comparison, seeks to interrupt the molecular instructions that allow cancer cells to grow, resist treatment, and evade the immune system, while minimizing harm to healthy tissue.
To illustrate this potential, Tiwari discusses the case of Layla, an infant diagnosed with acute lymphoblastic leukemia. After multiple rounds of chemotherapy and a bone marrow transplant failed to prevent her cancer from returning, her medical team turned to an experimental therapy involving genetically engineered immune cells. These cells, known as CAR-T cells, were modified to recognize a specific protein found on the surface of leukemia cells. Once infused into Layla’s body, the engineered cells were able to selectively target and destroy cancer cells while sparing healthy tissue. This ensured that the cells could function safely within her immune system without being rejected. Following treatment, no detectable leukemia remained. Tiwari presents this case as an example of how genetic engineering can create new therapeutic possibilities for patients who have exhausted conventional options.
A central conclusion of Tiwari’s review is that the greatest barrier to advancing genetic engineering is not scientific capability, but insufficient funding. Developing gene-based therapies requires years of laboratory research, extensive safety testing, and costly clinical trials. Without sustained investment, promising discoveries may stall before reaching patients. Scientific organizations have repeatedly warned that disruptions in research funding delay innovation and limit the translation of new technologies into routine cancer care.
Looking ahead, Tiwari frames genetic engineering as a bridge between today’s reactive cancer treatments and a future focused on durability and long-term prevention. By targeting cancer at its genetic roots, these approaches could reduce reliance on therapies with severe side effects, lower recurrence rates, and move oncology closer to truly personalized medicine. Cancer patients already shoulder immense uncertainty, but continued investment in genetic engineering offers a path toward treatments designed not only to extend life, but to protect it.